Post-earnings recap
Reported
Wed, Jul 29, 2026
EPS actual
$-0.14
EPS est.
$-0.28
EPS surprise
+49.28%
1-day move
+6.83%
Glaukos Corporation reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising by 6.83%. However, there was no revenue reported or guidance provided, leaving some uncertainty about future performance. Investors may view the EPS beat as a sign of improving financial health, but the lack of additional context from management could temper enthusiasm.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.14 | N/A | +49.28% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Glaukos Corporation is a healthcare company focused on developing innovative solutions for treating eye diseases, particularly glaucoma. With a market cap of $11 billion, it plays a significant role in the health care equipment sector, addressing a growing need for advanced ocular therapies.
Last quarter
In Q1 2026, Glaukos reported an EPS of -$0.18, outperforming expectations by 39.6%. However, the stock declined by 2.23% the following day, indicating mixed market reactions.
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+24.40%
Avg 1-day reaction
-0.05%
Investors are cautiously optimistic about Glaukos' upcoming earnings, given its history of beating EPS estimates. However, the stock's recent performance suggests uncertainty.
Bull case
If Glaukos can continue its trend of beating EPS estimates, it may see a positive reaction from the market, especially if revenue shows signs of growth.
Bear case
On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, as seen in previous quarters.
The print will turn on these.
Q1
What will be the EPS figure for Q2-2026?
The EPS result will be critical in determining whether Glaukos can maintain its trend of beating expectations and instill confidence in investors.
Q2
What guidance will management provide for the upcoming quarters?
Future guidance will help investors assess the company's growth trajectory and market position, especially in light of recent performance.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.5%
Why consensus could be wrong
The market may be underestimating Glaukos' ability to leverage its innovative product pipeline, which could lead to stronger-than-expected revenue growth.
Supporting evidence
Glaukos has consistently beaten EPS estimates in the past, suggesting a potential for continued outperformance.
The options market is pricing a larger move than historical averages, indicating heightened expectations for volatility.
Key risk
If the upcoming earnings show a significant improvement in revenue, it could challenge the current cautious sentiment.
Pre-commit to what would confirm each case.
The market is weighing the potential for continued earnings surprises against the backdrop of recent stock performance and broader market conditions.
Bull confirmed if
An EPS of -$0.10 or better would confirm the bull case and suggest strong operational performance.
Bear confirmed if
An EPS worse than -$0.30 would confirm the bear case and raise concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±7.87%
Historical Avg
±2.0%
The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.
Options are pricing ±7.9% while GKOS has averaged ±2.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
81.7%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$500,278.56
3,142 sh
1 insider
Net
$500,278.56
Net selling
Most Active Insiders· 7 open-market trades
$500,278.56
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
105.30%
of float
Insider
3.58%
of float
Holders
498
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
9,540,056 sh · $1.6B
16.17%
5.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Glaukos beats expectations, history suggests a potential stock increase of around 1.17% on the first day, confirming positive market sentiment.
In line / cautious
If the results are in line with expectations, the stock may see muted movement as investors await further commentary from management.
Miss
A disappointing report could lead to a decline of approximately 2.59% based on historical patterns, as investors react negatively to missed expectations.
The lines on the call that would change the story.
Recent Transactions
Sep 25, 2026 · @ $154.88
1,083 sh
$167,735.04
Oct 5, 2026 · @ $163.93
888 sh
$145,569.84
Oct 5, 2026 · @ $164.78
327 sh
$53,883.06
Oct 5, 2026 · @ $165.60
312 sh
$51,667.20
Sep 25, 2026 · @ $154.24
229 sh
$35,320.96
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Jupiter Topco LLC
4,862,894 sh · $837.3M
8.24%
100.0%
Vanguard Portfolio Management LLC
3,321,839 sh · $572.0M
5.63%
3.5%
Primecap Management Company
3,040,705 sh · $523.5M
5.16%
-9.8%
Vanguard Capital Management LLC
2,551,132 sh · $439.3M
4.33%
1.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.